8-K: InspireMD Announces Fourth Quarter and Full Year 2024 Financial Results, Awaits Potential FDA Approval for CGuard Prime

InspireMD reports increased revenue for Q4 and full year 2024, driven by growth in new and existing markets, while awaiting potential FDA approval for its CGuard Prime carotid stent system.

Summary

• InspireMD announced its financial and operating results for the fourth quarter and full year ended December 31, 2024.
• The company is awaiting potential FDA approval for its CGuard Prime carotid stent system, with a decision anticipated in the first half of 2025.
• InspireMD has established its headquarters in Miami, Florida, to support the anticipated U.S. commercial launch of CGuard Prime.
• Q4 2024 revenue increased by 10.7% to $1.949 million compared to $1.761 million in Q4 2023.
• Full year 2024 revenue increased by 13.0% to $7.009 million compared to $6.205 million in 2023.
• The net loss for Q4 2024 was $9.174 million, or $0.19 per share, compared to a net loss of $5.405 million, or $0.16 per share, for the same period in 2023.
• The net loss for the full year 2024 was $32.005 million, or $0.76 per share, compared to a net loss of $19.916 million, or $0.82 per share, for the full year 2023.
• As of December 31, 2024, cash and cash equivalents and marketable securities were $34.637 million compared to $39.023 million as of December 31, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, losses also increased significantly. The potential FDA approval is a positive catalyst, but the company's financial health remains a concern.

Positives

• InspireMD is awaiting potential FDA approval for its CGuard Prime carotid stent system in the U.S., expected in the first half of 2025.
• The company announced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures.
• InspireMD achieved quarterly revenue of $1.95 million and unit records of 3.5K in served markets.
• Full year 2024 revenue increased by 13.0% to $7.009 million compared to $6.205 million in 2023.

Negatives

• Gross profit for the fourth quarter of 2024 decreased by $36,000, or 7.1%, to $469,000, compared to a gross profit of $505,000 for the fourth quarter of 2023.
• Gross profit for the twelve months ended December 31, 2024, decreased by 16.7%, or $301,000, to $1,506,000, compared to a gross profit of $1,807,000 for the same period in 2023.
• The net loss for Q4 2024 was $9.174 million, or $0.19 per share, compared to a net loss of $5.405 million, or $0.16 per share, for the same period in 2023.
• The net loss for the full year 2024 was $32.005 million, or $0.76 per share, compared to a net loss of $19.916 million, or $0.82 per share, for the full year 2023.

Risks

• The company's future performance is subject to various risks and uncertainties, including the potential failure to secure and maintain regulatory approvals for the sale of its products.
• There is a risk that the data collected from current and planned clinical trials may not be sufficient to demonstrate that the technology is an attractive alternative to other procedures and products.
• The company faces intense competition in its industry, with competitors having substantially greater resources.
• The company has a history of recurring losses and negative cash flows from operating activities, raising substantial doubt about its ability to continue as a going concern.

Future Outlook

The company anticipates potential FDA approval and U.S. commercial launch of CGuard Prime in the first half of 2025, pending approval.

Management Comments

• Marvin Slosman, CEO of InspireMD, commented: 2024 was a year of tremendous progress at InspireMD.
• We advanced CGuard Prime, our best-in-class carotid implant, toward potential U.S. approval by submitting our PMA application to the FDA.
• We also initiated the CGUARDIANS II pivotal study for its use in the large and growing TCAR market an important step in expanding our development pipeline.
• We continue to see a clear path toward a potential CGuard Prime launch in the first half of 2025, pending approval.
• We are working closely with the FDA to support the review process and look forward to bringing this innovative technology to patients in the U.S.
• I look forward to key clinical, regulatory, and commercial milestones in the months ahead, particularly the potential U.S. approval and commercial launch of CGuard Prime, Mr. Slosman concluded.

Industry Context

InspireMD is focused on the carotid stent market, specifically addressing carotid artery disease and stroke prevention. The potential FDA approval of CGuard Prime would allow them to compete directly in the U.S. market, which is dominated by companies like Boston Scientific, Medtronic, and Abbott.

Comparison to Industry Standards

• InspireMD's CGuard Prime aims to compete with existing carotid stent systems from major players like Boston Scientific's Wallstent and Medtronic's Acculink.
• The success of CGuard Prime will depend on its clinical performance compared to these established products, particularly in terms of stroke prevention and long-term outcomes.
• The company's financial performance is modest compared to larger medical device companies, highlighting the importance of securing FDA approval and successfully launching CGuard Prime in the U.S. market.

Stakeholder Impact

• Shareholders are impacted by the increased net losses, but may see potential upside from FDA approval.
• Employees may benefit from the company's expansion in the U.S.
• Patients could benefit from the potential availability of CGuard Prime as a treatment option.

Next Steps

• Awaiting potential FDA approval for CGuard Prime in the U.S.
• Preparing for the potential U.S. commercial launch of CGuard Prime.
• Continuing the CGUARDIANS II pivotal study for TCAR procedures.

Key Dates